AxoGen (AXGN) Stock Analysis & AI Equity Report

Medical - Equipment & Services USD Explore free reports

AxoGen (AXGN) overview

AxoGen (AXGN) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 225m and operating profit of USD -7.8m; the year-end share price was 32.73 USD and market capitalisation was USD 1,545m. AxoGen is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get AxoGen's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 129mFY 2025
Share price32.73 USDFY 2025 year end
RevenueUSD 225mFY 2025
Operating profitUSD -7.8mFY 2025
Net earningsUSD -15.7mFY 2025
Market capitalisationUSD 1,545mFY 2025 year end

About AxoGen

AxoGen develops and commercializes technologies for peripheral nerve regeneration and repair, serving surgeons and healthcare providers treating nerve injuries. Its products include processed human nerve grafts, porcine tissue nerve connectors, protectors and caps, and a multilayer amniotic membrane tissue matrix. The portfolio is available in the United States and several other countries.

Generate the AxoGen report

AxoGen is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for AxoGen and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on AxoGen

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.